Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results (Q36070423)

12 August 2017

1 reference

title

Statins in hypertensive patients: potential explanations for the ASCOT-LLA study results (English)

1 reference

12 August 2017

0 references

Luis Miguel Blanco-Colio

1

1 reference

12 August 2017

Julio I Osende

2

1 reference

12 August 2017

Jose Luis Martín-Ventura

3

1 reference

12 August 2017

José Tuñón

4

1 reference

12 August 2017

Jesús Egido

5

1 reference

12 August 2017

publication date

1 January 2004

1 reference

12 August 2017

1 reference

12 August 2017

volume

64 Suppl 2

1 reference

12 August 2017

page(s)

61-67

1 reference

Hyperglycemia rapidly suppresses flow-mediated endothelium-dependent vasodilation of brachial artery.

12 August 2017

cites work

1 reference

12 December 2020

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

1 reference

12 December 2020

Involvement of Rho GTPases in the transcriptional inhibition of preproendothelin-1 gene expression by simvastatin in vascular endothelial cells

1 reference

12 December 2020

Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month

1 reference

12 December 2020

Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events

1 reference

12 December 2020

Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension

1 reference

12 December 2020

Statin prevents tissue factor expression in human endothelial cells: role of Rho/Rho-kinase and Akt pathways

1 reference

12 December 2020

Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease

1 reference

12 December 2020

Effect of cerivastatin sodium, a new inhibitor of HMG-CoA reductase, on plasma lipid levels, progression of atherosclerosis, and the lesional composition in the plaques of WHHL rabbits

1 reference

12 December 2020

Molecular mechanisms of angiotensin II-induced vascular injury.

1 reference

12 December 2020

Impaired endothelium-dependent vasodilation in patients with essential hypertension. Evidence that nitric oxide abnormality is not localized to a single signal transduction pathway

1 reference

12 December 2020

Statin-sensitive dysregulated AT1 receptor function and density in hypercholesterolemic men

1 reference

12 December 2020

Angiotensin II activates nuclear transcription factor kappaB through AT(1) and AT(2) in vascular smooth muscle cells: molecular mechanisms

1 reference

12 December 2020

Association between blood pressure and C-reactive protein levels in acute ischemic stroke

1 reference

12 December 2020

NF-kappaB activation and Fas ligand overexpression in blood and plaques of patients with carotid atherosclerosis: potential implication in plaque instability

1 reference

12 December 2020

An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro

1 reference

12 December 2020

Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT).

1 reference

12 December 2020

Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre ra

1 reference

12 December 2020

Increased bioavailability of nitric oxide after lipid-lowering therapy in hypercholesterolemic patients: a randomized, placebo-controlled, double-blind study

1 reference

12 December 2020

Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events (CARE) Investigators.

1 reference

12 December 2020

HMG-CoA reductase inhibitors improve endothelial dysfunction in normocholesterolemic hypertension via reduced production of reactive oxygen species

1 reference

12 December 2020

Nuclear factor-kappaB: a pivotal transcription factor in chronic inflammatory diseases

1 reference

12 December 2020

Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line

1 reference

12 December 2020

Decreased circulating Fas ligand in patients with familial combined hyperlipidemia or carotid atherosclerosis: normalization by atorvastatin

1 reference

12 December 2020

Endothelium-dependent relaxation by acetylcholine is impaired in hypertriglyceridemic humans with normal levels of plasma LDL cholesterol

1 reference

12 December 2020

HMG-CoA reductase inhibition by atorvastatin reduces neointimal inflammation in a rabbit model of atherosclerosis

1 reference

12 December 2020

HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells

1 reference

12 December 2020

The inducible transcription factor NF-kappa B: structure-function relationship of its protein subunits

1 reference

12 December 2020

Effect of hydroxymethyl glutaryl coenzyme a reductase inhibitor therapy on high sensitive C-reactive protein levels

1 reference

12 December 2020

Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion

1 reference

12 December 2020

Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitors

1 reference

12 December 2020

Effect of atorvastatin and bezafibrate on plasma levels of C-reactive protein in combined (mixed) hyperlipidemia

1 reference

12 December 2020

Simvastatin reduces NF-kappaB activity in peripheral mononuclear and in plaque cells of rabbit atheroma more markedly than lipid lowering diet

1 reference

12 December 2020

The ALLHAT-LLT and ASCOT-LLA trials: are the discrepancies more apparent than real?

1 reference

12 December 2020

TNFalpha regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation

1 reference

12 December 2020

Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization

1 reference

12 December 2020

Pravastatin therapy in hyperlipidemia: effects on thrombus formation and the systemic hemostatic profile

1 reference

12 December 2020

Inflammation and angiotensin II.

1 reference

12 December 2020

Atorvastatin reduces the expression of cyclooxygenase-2 in a rabbit model of atherosclerosis and in cultured vascular smooth muscle cells.

1 reference

12 December 2020

The nuclear factor kappa-B signaling pathway participates in dysregulation of vascular smooth muscle cells in vitro and in human atherosclerosis

1 reference

12 December 2020

Atorvastatin reduces NF-kappaB activation and chemokine expression in vascular smooth muscle cells and mononuclear cells

1 reference

12 December 2020

10.2165/00003495-200464002-00006

Identifiers

DOI

0 references

Dimensions Publication ID

1012815884

0 references

1 reference